Cyxone (publ) announced chief medical officer (CMO) Cornel Pater leaves the company with immediate effect due to personal reasons. The planned phase 2b study in rheumatoid arthritis (RA) is advancing and the intermediate situation will be covered by Cyxone's management team and medical advisors. Recruitment of a new CMO has started.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 SEK | -7.41% |
|
-12.28% | -0.40% |
14/05 | Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
22/04 | Sweden's Cyxone Appoints New CEO | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.40% | 2.2M | |
+4.96% | 70.02B | |
+16.65% | 9.05B | |
-22.81% | 4.43B | |
+14.83% | 4.16B | |
+19.21% | 3.83B | |
-1.86% | 2.06B | |
+8.78% | 2.02B | |
-36.94% | 1.9B | |
-45.25% | 1.71B |
- Stock Market
- Equities
- CYXO Stock
- News Cyxone AB
- Cyxone Announces Resignation of Cornel Pater as Chief Medical Officer